Drug Trial Radar · NCT00203684
Mentored Patient-Oriented Research Career Development Award
Last checked: Nov 20, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
57
Actual
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- University of California, Los AngelesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 20, 2005
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Asthmatics have inflammation in the large airways (tubes through which air travels in and out of the lungs). The large airways are located in the central lung. New research shows that asthmatics also have inflammation in the small airways. The small airways are located in the peripheral lung (the parts of the lung away from the central lung). Until now, most of the inhaled medications available have been made up of big particles that never reach the peripheral lung. The purpose of this study is to try to measure the level of inflammation in the peripheral lung in asthmatics and see if this inflammation can be decreased with different types of inhaled corticosteroids. The investigators will check airway inflammation before and after use of an inhaled corticosteroid that has a large particle size and should only reach the large airways (Flunisolide-CFC), and before and after use of an inhaled, small particle corticosteroid that should reach both the large and small airways (Flunisolide-HFA). Subjects will make 6 study visits over two phases of the study. In the first phase, the investigators will collect baseline information about subjects while they are using placebo (inactive substance). In the second phase, subjects will take either the large or small particle corticosteroid. Visits will involve questionnaires and various tests measuring lung function (such as spirometry, forced oscillation, and methacholine challenge). Exhaled nitric oxide will be measured as an indication of inflammation. Subjects will also measure and make note of lung function at home twice daily using a peak expiratory flow meter. Two of the visits will involve fiberoptic bronchoscopy so that the investigators may collect cells and tissue samples without surgery. Another two of the visits will involve the use of high resolution computed tomography (HRCT) scans to indirectly evaluate disease in distant parts of the lungs.
Conditions
- Asthma
- Distal Lung Inflammation
Interventions
Flunisolide-HFADrug
an inhaled, small particle corticosteroid that should reach both the large and small airways (Flunisolide-HFA)
Flunisolide-CFCDrug
an inhaled corticosteroid that has a large particle size and should only reach the large airways (Flunisolide-CFC)
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UCLA Asthma and Cough Center
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.